Singapore-headquartered Turion Labs has officially launched Southeast Asia’s first full-stack biotech innovation platform, designed to support start-ups and early-stage ventures in the region.
Backed by South Korea’s S&S LAB and Indonesia’s Future Lestari, the platform integrates shared laboratory infrastructure, contract research services, and regulatory enablement to accelerate the journey from discovery to market.
The announcement was made today during Ecosperity Week in Singapore.
The platform’s flagship site will open later this year at the Sinarmas Land Biomedical Hub in Indonesia’s Biomedical Special Economic Zone.
This facility will feature modular labs, pilot-scale research suites, and clinical support services, providing a comprehensive environment for biotech development. Dominic Jeong, CEO of S&S LAB Korea, stated, “We’re bridging the gap between high-potential science and scalable solutions.”
Turion Labs aims to address critical gaps in Southeast Asia’s biotech ecosystem by reducing capital and timeline barriers for new ventures and enhancing cross-border collaboration. Cynthia Krisanti, Director of Future Lestari, highlighted the platform’s role in enabling faster product development and expanded market access, saying, “Turion Labs is a platform for acceleration — a place where biotech ideas become real-world impact.”
The launch event was attended by Indonesia’s Coordinating Minister for Human Development and Cultural Affairs, who expressed support for the initiative. Turion Labs plans to expand beyond Singapore and Indonesia, with projects in Thailand, Malaysia, and the Philippines, creating a cross-border biotech corridor to attract venture capital and connect research hubs.
“`
